Illumina and GenoScreen Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
prnewswire.com
news
2022-10-18 10:00:00

Transformative alliance will help advance the World Health Organization's strategy to end the global TB epidemic by 2035SAN DIEGO, Oct. 18, 2022 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics company, today announced a partnership to accelerate progress to end tuberculosis (TB) worldwide. The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB (MDR-TB).
